Mucinous Ovarian Tumors.
Mills AM, Shanes ED.
Surg Pathol Clin. 2019 Jun;12(2):565-585. doi: 10.1016/j.path.2019.01.008.
Mucinous Ovarian Carcinoma.
Morice P, Gouy S, Leary A.
N Engl J Med. 2019 Mar 28;380(13):1256-1266. doi: 10.1056/NEJMra1813254.
Mucinous ovarian cancer.
Harrison ML, Jameson C, Gore ME.
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209-14. doi: 10.1111/j.1525-1438.2007.01022.x. Epub 2007 Jul 11.
Mucinous Ovarian Carcinoma.
Hackshaw A, Gershenson D, Ledermann J.
N Engl J Med. 2019 Jul 4;381(1):e3. doi: 10.1056/NEJMc1905728.
A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.
Yang L, Yu J, Zhang S, Shan Y, Li Y, Xu L, Zhang J, Zhang J.
J Ovarian Res. 2022 Feb 16;15(1):26. doi: 10.1186/s13048-022-00958-6.
Molecular and immunohistochemical markers in appendiceal mucinous neoplasms: A systematic review and comparative analysis with ovarian mucinous neoplasms and colorectal adenocarcinoma.
Elsayed B, Elshoeibi AM, Elhadary M, Al-Jubouri AM, Al-Qahtani N, Vranic S, Al-Saady R.
Histol Histopathol. 2025 May;40(5):621-633. doi: 10.14670/HH-18-830. Epub 2024 Oct 10.
Mucinous Ovarian Carcinoma. Reply.
Morice P, Leary A, Gouy S.
N Engl J Med. 2019 Jul 4;381(1):e3. doi: 10.1056/NEJMc1905728.
KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
Hershkovitz D, Vlodavsky E, Simon E, Ben-Izhak O.
Pathol Int. 2013 Dec;63(12):611-4. doi: 10.1111/pin.12123.
Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
Moioli M, Barra F, Maramai M, Valenzano Menada M, Vellone VG, Costantini S, Ferrero S.
Expert Opin Investig Drugs. 2019 Dec;28(12):1025-1029. doi: 10.1080/13543784.2019.1693999. Epub 2019 Nov 19.
Recent Insights into Mucinous Ovarian Carcinoma.
Ricci F, Affatato R, Carrassa L, Damia G.
Int J Mol Sci. 2018 May 24;19(6):1569. doi: 10.3390/ijms19061569.
